Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary
Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and…
Halozyme Announces Commercial Launch Of TLANDO, An Oral Treatment For Testosterone Replacement Therapy
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the commercial launch of TLANDO™ (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in
Goldman Sachs Maintains Buy on Halozyme Therapeutics, Raises Price Target to $60
Goldman Sachs maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $48 to $60.
MindMed Appoints Schond L. Greenway As CFO
Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO.
Recap: Halozyme Therapeutics Q1 Earnings
Halozyme Therapeutics (NASDAQ:HALO) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell
• The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
Halozyme Therapeutics’s Earnings Outlook
Halozyme Therapeutics (NASDAQ:HALO) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement.
Analysts estimate that Halozyme Therapeutics will report an earnings per share (EPS) of $0.49.
Halozyme Reports Tender Offer To Buy All Shares Of Antares Pharma At $5.60/Share In Cash
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. ("Purchaser"), a cash tender offer to
Why Antares Pharma Stock Is Soaring Today
Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO) for $5.60 per share in cash, valuing Antares at